simvastatin has been researched along with Fatty Liver, Nonalcoholic in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (61.11) | 24.3611 |
| 2020's | 7 (38.89) | 2.80 |
| Authors | Studies |
|---|---|
| Araujo, BP; Daliry, A; Fernandes-Santos, C; Flores, EEI; Martins, CSM; Pereira, ENGDS; Rodrigues, KL; Silvares, RR | 1 |
| Bumbasirevic, V; Ciric, D; Jovanovic, S; Kravic-Stevovic, T; Martinovic, T; Petricevic, S; Trajkovic, V | 1 |
| Harkema, J; Jurgelewicz, A; LaPres, JJ; Nault, R; Zacharewski, TR | 1 |
| Ampawong, S; Burana-Osot, J; Chantip, S; Isarangkul, D; Kanjanapruthipong, T; Kengkoom, K; Phattanawasin, P; Sotanaphun, U; Tirawanchai, N | 1 |
| Fras, Z; Mikhailidis, DP | 1 |
| Armas Flórez, CD; Concepción-Zavaleta, MJ; Gonzáles Yovera, JG; Moreno Marreros, DM | 1 |
| Li, Z; Lin, Z; Lyu, Y; Poon, LH; To, KKW; Yan, X; Zhang, J; Zhang, Y; Zhao, J; Zhou, L; Zuo, Z | 1 |
| Li, P; Lu, YW; Wen, XD; Yang, J; Zhang, L; Zhu, YC | 1 |
| Chong, GH; Ghazali, HM; Hamzah, H; Tan, CX | 1 |
| Bona, S; Di Naso, FC; Dias, AS; Marroni, CA; Marroni, NP; Moreira, AJ; Picada, JN; Pires, TR; Rodrigues, G; Schemitt, E | 1 |
| Björnsson, E; Enders, F; Lindor, KD; Suwanwalaikorn, S; Treeprasertsuk, S | 1 |
| Shen, C; Wang, W; Wang, Y; Zhao, C; Zhen, Z; Zhou, J | 1 |
| Qin, S; Sang, H; Si, Y; Wang, J; Xu, X; Yang, N; Yao, S; Zhai, L; Zhang, Y; Zu, D | 1 |
| Aramin, H; Eslami, L; Malekzadeh, R; Merat, S; Nasseri-Moghaddam, S | 1 |
| Canet, MJ; Cherrington, NJ; Clarke, JD; Hardwick, RN; Lake, AD | 1 |
| D'Angelo, A; Derosa, G; Maffioli, P; Mugellini, A; Pesce, RM | 1 |
| Al Humayed, S | 1 |
| Braga, TT; Franklin, BS; Hittatiya, K; Klein, S; Latz, E; Lütjohann, D; Maybüchen, L; Nickenig, G; Plat, J; Sauerbruch, T; Schierwagen, R; Strassburg, CP; Trebicka, J; Uschner, FE; Zimmer, S | 1 |
1 review(s) available for simvastatin and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Topics: Alanine Transaminase; Atorvastatin; Fatty Liver; Fenofibrate; gamma-Glutamyltransferase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Non-alcoholic Fatty Liver Disease; Pyrroles; Simvastatin | 2013 |
2 trial(s) available for simvastatin and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Have We Learnt all from IMPROVE-IT? Part I. Core Results and Subanalyses on the Effects of Ezetimibe Added to Statin Therapy Related to Age, Gender and Selected Chronic Diseases (Kidney Disease, Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease).
Topics: Aged; Anticholesteremic Agents; Chronic Disease; Diabetes Mellitus; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Male; Non-alcoholic Fatty Liver Disease; Simvastatin; Treatment Outcome | 2021 |
Perindopril and barnidipine alone or combined with simvastatin on hepatic steatosis and inflammatory parameters in hypertensive patients.
Topics: Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Hypolipidemic Agents; Male; Nifedipine; Non-alcoholic Fatty Liver Disease; Obesity; Perindopril; Simvastatin | 2015 |
15 other study(ies) available for simvastatin and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Simvastatin Improves Microcirculatory Function in Nonalcoholic Fatty Liver Disease and Downregulates Oxidative and ALE-RAGE Stress.
Topics: Animals; Mice; Microcirculation; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Simvastatin | 2022 |
Effects of metformin and simvastatin treatment on ultrastructural features of liver macrophages in HFD mice.
Topics: Animals; Diabetes Mellitus, Type 2; Diet, High-Fat; Liver; Macrophages; Metformin; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Simvastatin | 2023 |
Characterizing the impact of simvastatin co-treatment of cell specific TCDD-induced gene expression and systemic toxicity.
Topics: Animals; Cholesterol; Gene Expression; Humans; Liver; Male; Mice; Non-alcoholic Fatty Liver Disease; Polychlorinated Dibenzodioxins; Receptors, Aryl Hydrocarbon; Simvastatin | 2023 |
A combination extract of kaffir lime, galangal, and lemongrass maintains blood lipid profiles, hepatocytes, and liver mitochondria in rats with nonalcoholic steatohepatitis.
Topics: Alpinia; Animals; Antioxidants; Citrus; Cymbopogon; Hepatocytes; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Male; Mitochondria, Liver; Non-alcoholic Fatty Liver Disease; Plant Extracts; Rats; Rats, Sprague-Dawley; Simvastatin | 2020 |
Statins in liver cirrhosis in a developing country: benefits overweigh the risk?
Topics: Chemical and Drug Induced Liver Injury; Contraindications, Drug; Developing Countries; Hepatitis, Viral, Human; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver Cirrhosis; Meta-Analysis as Topic; Non-alcoholic Fatty Liver Disease; Obesity; Peru; Risk Assessment; Simvastatin | 2020 |
Intestinal absorption and hepatic elimination of drugs in high-fat high-cholesterol diet-induced non-alcoholic steatohepatitis rats: exemplified by simvastatin.
Topics: Animals; Cholesterol; Diet, High-Fat; Hepatobiliary Elimination; Humans; Intestinal Absorption; Liver; Non-alcoholic Fatty Liver Disease; Pharmaceutical Preparations; Rats; Simvastatin | 2021 |
Ilexgenin A enhances the effects of simvastatin on non-alcoholic fatty liver disease without changes in simvastatin pharmacokinetics.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Cytochrome P-450 CYP3A; Diet, High-Fat; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Lipids; Liver; Male; Molecular Structure; Non-alcoholic Fatty Liver Disease; Rats; Rats, Sprague-Dawley; Simvastatin; Transcription, Genetic; Triterpenes | 2018 |
Effect of virgin avocado oil on diet-induced hypercholesterolemia in rats via
Topics: Animals; Atherosclerosis; Diet, High-Fat; Hypercholesterolemia; Lipids; Liver; Magnetic Resonance Spectroscopy; Male; Metabolomics; Non-alcoholic Fatty Liver Disease; Persea; Plant Oils; Rats; Rats, Sprague-Dawley; Simvastatin; Urinalysis | 2018 |
Simvastatin Reduces Hepatic Oxidative Stress and Endoplasmic Reticulum Stress in Nonalcoholic Steatohepatitis Experimental Model.
Topics: Animals; Antioxidants; Choline Deficiency; Endoplasmic Reticulum Stress; Glutathione Peroxidase; Inflammation; Liver; Male; Methionine; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Simvastatin; Superoxide Dismutase | 2019 |
NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients.
Topics: Adult; Aged; Aged, 80 and over; Biopsy; Cause of Death; Chi-Square Distribution; Decision Support Techniques; Fatty Liver; Female; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Liver Cirrhosis; Logistic Models; Male; Metformin; Middle Aged; Minnesota; Multivariate Analysis; Non-alcoholic Fatty Liver Disease; Odds Ratio; Predictive Value of Tests; Prognosis; Risk Factors; Severity of Illness Index; Simvastatin; Time Factors; Young Adult | 2013 |
Simvastatin ameliorates liver fibrosis via mediating nitric oxide synthase in rats with non-alcoholic steatohepatitis-related liver fibrosis.
Topics: Actins; Animals; Cells, Cultured; Collagen Type I; Diet, High-Fat; Enzyme Inhibitors; Fatty Liver; Gene Expression; Hepatic Stellate Cells; Humans; Hypolipidemic Agents; Liver; Liver Cirrhosis; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Non-alcoholic Fatty Liver Disease; Rats; Rats, Wistar; Simvastatin; Transforming Growth Factor beta1 | 2013 |
Celastrus orbiculatus Thunb. ameliorates high-fat diet-induced non-alcoholic fatty liver disease in guinea pigs.
Topics: Animals; Body Weight; Celastrus; Cholesterol; Cholesterol, LDL; Diet, High-Fat; Fatty Liver; Guinea Pigs; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Liver; Liver Function Tests; Male; Malondialdehyde; Nitric Oxide; Nitric Oxide Synthase Type II; Non-alcoholic Fatty Liver Disease; Organ Size; Real-Time Polymerase Chain Reaction; Simvastatin; Superoxide Dismutase | 2013 |
Experimental nonalcoholic steatohepatitis increases exposure to simvastatin hydroxy acid by decreasing hepatic organic anion transporting polypeptide expression.
Topics: Animals; Down-Regulation; Fatty Liver; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Male; Non-alcoholic Fatty Liver Disease; Organic Anion Transporters; Rats; Rats, Sprague-Dawley; Simvastatin | 2014 |
Protective and therapeutic effects of Crataegus aronia in non-alcoholic fatty liver disease.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Crataegus; Diet, Fat-Restricted; Diet, High-Fat; Jordan; Lipotropic Agents; Liver; Male; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Plant Components, Aerial; Plant Extracts; Random Allocation; Rats, Wistar; Simvastatin | 2017 |
Statins improve NASH via inhibition of RhoA and Ras.
Topics: Animals; Apolipoproteins E; Cholesterol; Diet, Western; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Mice; Mice, Knockout; Non-alcoholic Fatty Liver Disease; ras Proteins; rhoA GTP-Binding Protein; Signal Transduction; Simvastatin | 2016 |